Biological events that contribute to the pathogenesis of myelodysplastic
syndromes/neoplasms (MDS) are becoming increasingly characterized and are being …

The guidelines for classification, prognostication, and response assessment of
myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report …

In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS)
have been proposed: the International Consensus Classification (ICC) and the 2022 World …

Acute myeloid leukemia with antecedent hematologic disorder (AHD-AML) and therapy
related AML (t-AML) constitute a heterogenous disease with inferior outcomes. It is often …

Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically
distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 …

Morphologic characterization remains a cornerstone in the diagnosis and classification of
myelodysplastic syndromes (MDS) in the updated International Consensus Classification …

TP53 mutation predicts adverse prognosis in many cancers, including myeloid neoplasms,
but the mechanisms by which specific mutations affect disease biology, and whether they …

This article intends to summarize and comment on some of the highlights regarding
myelodysplastic syndrome (MDS) presented at the 2022 American Society of Hematology …

In 2022, both the World Health Organization 1 (WHO) and the International Consensus
Classification (ICC) 2 revised their guidelines for classifications of myeloid neoplasms. At …